UrgentIQ Raises $15 Million to Build an EMR Made for Urgent Care

UrgentIQ, a New York-based healthcare technology company, has raised a $15 million Series A growth investment from Five Elms Capital, a firm with more than $3 billion in assets under management and a track record of backing more than 70 software platforms.

Founded by Nat Gibbs, UrgentIQ built its electronic medical record system specifically for urgent care centers rather than adapting a system designed for hospitals or primary care, and the company reports a 9.7 out of 10 average customer satisfaction rating as a result. The funding will accelerate an expansion beyond core EMR functionality into a broader clinical and financial operating platform, with planned capabilities including automated revenue cycle management, AI-powered diagnosis and documentation support, live insurance verification, and an AI checkout agent.

Why purpose-built beats adapted in a niche care setting

Urgent care operates on fundamentally different economics than a hospital or primary care practice: speed, throughput, documentation, coding, and collections are all tightly interconnected in a setting where patients expect to be seen and treated in a single fast visit. Legacy EMRs built for hospital workflows or slower-paced primary care visits often force urgent care operators into workarounds. UrgentIQ's from-the-ground-up approach to that specific workflow is the core argument behind its high satisfaction scores, and behind Five Elms's decision to back an expansion into adjacent financial and clinical tools rather than a new market entirely.

A growth round, not a Series A in name only

Five Elms describes this as a "strategic growth investment" rather than a traditional Series A, a distinction worth noting. Growth-stage investors like Five Elms typically look for a company that has already proven its core product works at scale, evidenced here by the 9.7 satisfaction score across a real customer base, and are funding expansion into adjacent products rather than funding the search for product-market fit itself. That's a meaningfully lower-risk investment thesis than a typical Series A, and it shows in the syndicate: a single growth-focused investor with a deep software portfolio, rather than a broader syndicate of earlier-stage venture funds.

What this means for founders

UrgentIQ's growth investment, arriving well after its original product-market fit was established in a genuinely narrow niche, is a useful model for founders building vertical-specific software: winning a narrow category completely, evidenced here by a 9.7 satisfaction score, can be a stronger foundation for a follow-on raise than a broader, shallower approach to a larger market. Investors backing vertical software increasingly want proof of category dominance in the original niche before funding expansion into adjacent products.

Healthtech and vertical SaaS investors can be found on the investor directory, and the free investor matching tool scores fit for founders expanding a proven vertical product into adjacent categories. Background on how growth-stage rounds differ from earlier rounds is in the glossary entry on growth stage valuation. Currently live raises are on the live listings page, and broader healthtech funding activity is tracked on the newsroom.

Find investors who are actively deploying by creating your pitch listing on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai